$135.54
0.21% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
US00846U1016
Symbol
A
Sector
Industry

Agilent Technologies Stock price

$135.54
-2.60 1.88% 1M
+4.74 3.62% 6M
-3.49 2.51% YTD
-4.28 3.06% 1Y
-23.20 14.62% 3Y
+50.12 58.67% 5Y
+94.21 227.95% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.29 0.21%
ISIN
US00846U1016
Symbol
A
Sector
Industry

Key metrics

Market capitalization $38.71b
Enterprise Value $40.95b
P/E (TTM) P/E ratio 30.62
EV/FCF (TTM) EV/FCF 29.83
EV/Sales (TTM) EV/Sales 6.29
P/S ratio (TTM) P/S ratio 5.95
P/B ratio (TTM) P/B ratio 6.55
Dividend yield 0.70%
Last dividend (FY24) $0.94
Revenue growth (TTM) Revenue growth -4.73%
Revenue (TTM) Revenue $6.51b
EBIT (operating result TTM) EBIT $1.60b
Free Cash Flow (TTM) Free Cash Flow $1.37b
Cash position $1.33b
EPS (TTM) EPS $4.43
P/E forward 27.43
P/S forward 5.67
EV/Sales forward 6.00
Short interest 1.36%
Show more

Is Agilent Technologies a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Agilent Technologies Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Agilent Technologies forecast:

9x Buy
43%
11x Hold
52%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a Agilent Technologies forecast:

Buy
43%
Hold
52%
Sell
5%

Financial data from Agilent Technologies

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
6,510 6,510
5% 5%
100%
- Direct Costs 2,948 2,948
5% 5%
45%
3,562 3,562
5% 5%
55%
- Selling and Administrative Expenses 1,257 1,257
6% 6%
19%
- Research and Development Expense 452 452
6% 6%
7%
1,853 1,853
3% 3%
28%
- Depreciation and Amortization 257 257
5% 5%
4%
EBIT (Operating Income) EBIT 1,596 1,596
3% 3%
25%
Net Profit 1,289 1,289
4% 4%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Agilent Technologies directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agilent Technologies Stock News

Neutral
Business Wire
9 days ago
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agil...
Neutral
Business Wire
19 days ago
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic m...
Positive
Seeking Alpha
about one month ago
I reiterate a “Buy” rating on Agilent Technologies, Inc. with a one-year target price of $150 per share, driven by strategic growth and market recovery. Agilent's acquisition of BIOVECTRA will enhance its CDMO business, focusing on oligonucleotides and CRISPR therapeutics, and expand service offerings in peptide synthesis. Agilent's FY25 guidance includes 2.5%-3.5% core revenue growth and 5.8% ...
More Agilent Technologies News

Company Profile

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Head office United States
CEO Padraig Mcdonnell
Employees 17,900
Founded 1999
Website www.agilent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today